GDF15 Analogues Acting as GFRAL Ligands

Growth differentiation factor 15 (GDF15) is a TGF‐β superfamily member involved in diverse physiological and pathological processes. It is expressed in various tissues and its circulating levels rise during exercise, aging, pregnancy, and conditions such as cancer, cardiovascular disease, and infections. The biological activities of GDF15, including anorexia and cachexia, are primarily mediated through the GFRAL receptor, localized in the brainstem and functioning via RET co‐receptor recruitment. This signaling is crucial for energy homeostasis and nausea induction. Recent studies suggest a broader GFRAL distribution, potentially explaining GDF15's distinct roles. These findings sparked interest in leveraging GDF15‐GFRAL pathways for therapeutic development. Two primary strategies include GDF15 analogues as GFRAL agonists for obesity treatment and GDF15‐derived peptides as antagonists to counteract cancer‐induced cachexia and related disorders. This review highlights advancements in understanding GDF15‐GFRAL signaling and its implications, summarizing bioactive GDF15‐derived molecules, their pharmacological applications, and offering insights into novel treatment avenues for GDF15‐associated conditions.